Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Capital Expenditures for 12 consecutive years, with -$390000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 300.0% to -$390000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $467000.0 through Dec 2025, down 68.06% year-over-year, with the annual reading at $467000.0 for FY2025, 68.06% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$390000.0 at Madrigal Pharmaceuticals, down from $857000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $1.0 million in Q4 2023, with the low at -$390000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $213000.0, with a median of $86000.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 5050.0% in 2022, then tumbled 300.0% in 2025.
  • Over 5 years, Capital Expenditures stood at $113000.0 in 2021, then crashed by 74.34% to $29000.0 in 2022, then skyrocketed by 3472.41% to $1.0 million in 2023, then plummeted by 81.18% to $195000.0 in 2024, then crashed by 300.0% to -$390000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$390000.0, $857000.0, and $195000.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.